enVVeno Medical Corp
NASDAQ:NVNO

Watchlist Manager
enVVeno Medical Corp Logo
enVVeno Medical Corp
NASDAQ:NVNO
Watchlist
Price: 2.49 USD -1.58% Market Closed
Market Cap: 43.7m USD
Have any thoughts about
enVVeno Medical Corp?
Write Note

enVVeno Medical Corp
Other Long-Term Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

enVVeno Medical Corp
Other Long-Term Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Long-Term Assets CAGR 3Y CAGR 5Y CAGR 10Y
enVVeno Medical Corp
NASDAQ:NVNO
Other Long-Term Assets
$31k
CAGR 3-Years
-15%
CAGR 5-Years
-48%
CAGR 10-Years
N/A
Becton Dickinson and Co
NYSE:BDX
Other Long-Term Assets
$2.6B
CAGR 3-Years
10%
CAGR 5-Years
19%
CAGR 10-Years
18%
Boston Scientific Corp
NYSE:BSX
Other Long-Term Assets
$4.5B
CAGR 3-Years
-1%
CAGR 5-Years
19%
CAGR 10-Years
28%
Stryker Corp
NYSE:SYK
Other Long-Term Assets
$3.9B
CAGR 3-Years
3%
CAGR 5-Years
9%
CAGR 10-Years
18%
Abbott Laboratories
NYSE:ABT
Other Long-Term Assets
$8B
CAGR 3-Years
26%
CAGR 5-Years
28%
CAGR 10-Years
8%
Intuitive Surgical Inc
NASDAQ:ISRG
Other Long-Term Assets
$1.6B
CAGR 3-Years
21%
CAGR 5-Years
17%
CAGR 10-Years
28%
No Stocks Found

enVVeno Medical Corp
Glance View

Market Cap
43.7m USD
Industry
Health Care

enVVeno Medical Corp. is a development stage medical device company, which develops tissue based solutions that are designed to be life sustaining or life enhancing for patients with cardiovascular disease, and peripheral arterial and venous disease. The company is headquartered in Irvine, California and currently employs 24 full-time employees. The company went IPO on 2018-05-31. The firm is focused on improving the standard of care in the treatment of venous disease. The firm is focused on developing tissue-based solutions that are designed for patients with chronic venous insufficiency (CVI). Its lead product, VenoValve, is a porcine based device being developed to surgically implanted in the deep venous system of the leg to treat severe CVI, including the potential to heal recurring venous leg ulcers. The VenoValve is designed to be implanted into the femoral vein of the patient in an open surgical procedure via a five-to-six-inch incision in the upper thigh. The VenoValve is being evaluated in the surgical anti-reflux venous valve endoprosthesis (SAVVE) United States clinical trial. In addition to the VenoValve, the Company is focused on the development of a second device, enVVe, for the treatment of venous disease.

NVNO Intrinsic Value
Not Available

See Also

What is enVVeno Medical Corp's Other Long-Term Assets?
Other Long-Term Assets
31k USD

Based on the financial report for Sep 30, 2024, enVVeno Medical Corp's Other Long-Term Assets amounts to 31k USD.

What is enVVeno Medical Corp's Other Long-Term Assets growth rate?
Other Long-Term Assets CAGR 5Y
-48%

Over the last year, the Other Long-Term Assets growth was -56%. The average annual Other Long-Term Assets growth rates for enVVeno Medical Corp have been -15% over the past three years , -48% over the past five years .

Back to Top